… that endurance is both a physical and emotional feat. From the moment I announced my climb with Team Fox in June … so personal made this climb incredibly meaningful. Being from Oklahoma, hiking isn’t exactly in my backyard, but that hasn’t stopped me from chasing peaks. Every summer, I head to Colorado to …

… findings ultimately could be used to request approval from regulatory agencies, like the U.S. Food and Drug … a drug’s effectiveness, side effects and safety, and data from these trials are critical to securing FDA approval. The … this testing. In one innovation, Roche used PPMI data from people with Parkinson’s at similar stages to those who …

… patient community moving forward. Read on to hear directly from our team about some of 2012’s most exciting … with PD . In partnership with Kinetics, we convened experts from the Parkinson’s space and across other neurological … Particularly exciting this year: positive clinical results from Addex Therapeutics into their drug called dipraglurant. …

… and progression. If researchers can prevent the protein from clumping into Lewy bodies, clear them out or stop their spread from cell to cell, they may stop Parkinson's disease (PD). … to help design others. Here we share the latest updates from the field of alpha-synuclein clinical trials. …

… Currently, orally delivered levodopa products suffer from complications, possibly arising from pulsatile blood levels, typically encountered after … drug product. A high degree of safety was indicated from an 18-day study in which the final form of HLT-311 …

… performing and renewable antibodies so that all researchers can utilize the same antibody tools when testing … will be stored frozen at a repository and made available to researchers as a resource to determine whether certain … period (a diurnal fluctuation). The results will inform researchers about the variability of the biomarker in …